Systemic Mastocytosis with Associated Primary Myelofibrosis

1 23

Indian Journal of Hematology and

Blood Transfusion

ISSN 0971-4502

Indian J Hematol Blood Transfus

DOI 10.1007/s12288-019-01225-3

Systemic Mastocytosis with Associated

Primary Myelofibrosis

Marianna Greco, Giovanni Caocci,

Roberto Mascia, Sonia Nemolato,

Margherita Deidda, Maria Pina Simula,

Maria Pina Barca, et al.

1 23

Your article is protected by copyright and all

rights are held exclusively by Indian Society

of Hematology and Blood Transfusion. This

e-offprint is for personal use only and shall not

be self-archived in electronic repositories. If

you wish to self-archive your article, please

use the accepted manuscript version for

posting on your own website. You may

further deposit the accepted manuscript

version in any repository, provided it is only

made publicly available 12 months after

official publication or later and provided

acknowledgement is given to the original

source of publication and a link is inserted

to the published article on Springer's

website. The link must be accompanied by

the following text: "The final publication is

available at link.springer.com”.

I M A G E S

Systemic Mastocytosis with Associated Primary Myelofibrosis

Marianna Greco1•_{Giovanni Caocci}2 •_{Roberto Mascia}3•_{Sonia Nemolato}1•

Margherita Deidda4•_{Maria Pina Simula}2•_{Maria Pina Barca}4• _{Sandra Orru`}1•

Giorgio La Nasa2

Received: 29 September 2019 / Accepted: 19 October 2019 Ó Indian Society of Hematology and Blood Transfusion 2019

Keywords Systemic mastocytosis
Myelofibrosis
SM-AHN
KIT

Systemic mastocytosis (SM) is a chronic myeloprolifera-tive neoplasm characterized by the infiltration of atypical mast cells (MC). The major SM diagnostic criterion is the multifocal clustering of mast cells in the bone marrow. Minor SM criteria include an abnormal MC morphology and expression of CD25/CD2, an activating mutation at codon 816 of KIT, and a persistent serum tryptase con-centration of [ 20 ng/mL. When the major and at least 1 minor criterion or 3 minor criteria are fulfilled, the SM diagnosis is established. The World Health Organization (WHO) classification has recently recognized a subgroup of SM with an associated hematological neoplasm (SM-AHN), which is characterized by the presence of a con-current neoplasm [1]. We present the case of a 72-year old

woman suffering from SM associated with myelofibrosis (MF) referred to our center due to mild anemia and leukocytosis (Hb, 10.2 g/dL, WBC, 11,900/mm3, PLT, 368,000/mm3). The patient complained of fatigue, pruritus and weight loss. Physical examination revealed spleno-megaly; Jak2V617F mutation and c-kit D816V mutation were detected. Basal tryptase value was 80.4 ng/mL.

Bone marrow flow cytometry showed aberrant CD2-CD25 expression in 5.5% of MC.

The bone marrow trephine biopsy showed:

A. Maturation defects of megakaryocytes with bulbous and naked nuclei (H&E, 20 9); B. Diffuse and dense increase in reticulin fibers (MF2) (Argentic staining, 20 9); C. Mastocytes are round to spindle-shaped cells, which have a clarified cytoplasm organized in aggregates of more than 15 elements (H&E, 40 9); D. Marked CD117 cytoplasmic positivity in MC (40 9).

& Giovanni Caocci giovanni.caocci@unica.it

1 _{Anatomia Patologica, P.O. Businco, Azienda Ospedaliera}

Brotzu, Cagliari, Italy

2 _{Dipartimento di Scienze Mediche e Sanita` Pubblica, SC}

Ematologia e CTMO, Ospedale Businco, P.O. Businco, Universita` di Cagliari, Azienda Ospedaliera Brotzu, Via Jenner, sn, 09124 Cagliari, Italy

3 _{Anatomia Paologica, P.O. SS. Trinita`, Azienda Tutela Salute}

Sardegna, Cagliari, Italy

4 _{Allergologia e Immunologia clinica, Policlinico, Azienda}

Ospedaliera Universitaria, Universita` di Cagliari, Cagliari, Italy

123

Indian J Hematol Blood Transfus

https://doi.org/10.1007/s12288-019-01225-3

We described the second case of association between SM and MF on the basis of the 2016 WHO classification. Xu and Xu previously reported a myeloproliferative neo-plasm with splenomegaly in a 62-year-old woman. Biopsy results showed MF3 fibrosis and CD117 highlighted mul-tifocal infiltrates of spindle-shaped/atypical MC in aggre-gates, consistent with the diagnosis of SM-AHN per 2016 WHO criteria [2].

Patients with SM often report unspecific symptoms secondary to histamine MC degranulation such as head-ache attacks, skin flushing, hypotensive crises, tachycardia, gastrointestinal complaints, osteopenia or osteoporosis. The most common triggers is an acute anaphylactoid reaction, caused by wasp or bee stings. Our patient was prescribed adrenaline fastject in case of anaphylactic reaction and started a treatment based on histamine H1-and H2-antagonist.

According to the International Prognostic Scoring Sys-tem (IPSS) for MF (age [ 60; WBC [ 25,000/mm3; blast in blood [ 1%; Hb \ 10 g/dL and systemic B symptoms), the patient was considered intermediate-2 score, with a

median survival time of 48 months (range 3–59). She was initially treated with low dose of hydroxyurea (500 mg/day) and it is planned to start with ruxolitinib [3].

References

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Beau MML et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405

2. Xu RZ, Xu Z (2018) Systemic mastocytosis with an associated hematological neoplasm masquerading as overt primary myelofi-brosis. Blood 132(24):2613

3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Indian J Hematol Blood Transfus

123